Dr. Singh on the Role of Chemotherapy in Bladder Cancer

Video

In Partnership With:

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the evolving role of chemotherapy in the treatment of bladder cancer.

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the evolving role of chemotherapy in the treatment of bladder cancer.

The rise of immunotherapy in bladder cancer gave oncologists optimism that they could shy away from chemotherapy, Singh says, but right now it appears that not enough patients are responding to checkpoint inhibitors. In other disease types like lung cancer, data show that chemotherapy in combination with immunotherapy is improving outcomes for patients. As a result, chemotherapy is likely to make a comeback in bladder cancer in terms of sensitizing the immune system to immunotherapy.

Chemotherapy is believed to be immunosuppressive, but recent findings indicate it can make a tumor “hot,” meaning that it will allow the body to naturally fight the disease with its immune system. Singh concludes that chemotherapy will evolve in bladder cancer treatment to be used with immunotherapy.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD